Clinical Cardiology Alert – October 1, 2012
October 1, 2012
View Issues
-
FFR-Guided PCI vs Medical Therapy in Stable Coronary Artery Disease
In patients with stable coronary artery disease (CAD), medical therapy is the mainstay of treatment. Percutaneous coronary intervention (PCI) guided by angiographic stenosis is more effective than medical therapy at reducing angina, but does not change the rate of death or myocardial infarction (MI). -
IABP for MI with Cardiogenic Shock?
Patients who present with acute myocardial infarction (MI) complicated by cardiogenic shock represent a group at high risk for early mortality. -
Management of Atrial Fibrillation in Chronic Kidney Disease Patients
Patients with chronic kidney disease or who have had renal replacement therapy have often been excluded from trials of anticoagulation in atrial fibrillation (AF). In this study, the authors analyzed data from hospitalized patients with nonvalvular AF in Denmark from 1997 through 2008. Patients with chronic kidney disease with and without renal replacement therapy were identified from a national registry. -
Stroke Risk with Warfarin Interruption
The risk of interrupting prophylactic warfarin for stroke prevention in atrial fibrillation (AF) patients is unclear. Thus, these investigators from Denmark evaluated their national health registry and found 102,591 patients > age 30 with a first-time hospitalization for AF between 1997 and 2008. -
Riata ICD Lead Defects
More than 200,000 Riata family implantable cardioverter-defibrillator (ICD) leads from St. Jude Medical were implanted worldwide. Recently, the FDA issued a Class I recall on this lead because of the appearance of defects in the lead insulation that may lead to externalization of the conductor wires. -
Pharmacology Watch: Statins and Cognition — More to the Story?
Side effects of statins; effects of cannabis use; antihypertensives and lip cancer; and FDA actions. -
Clinical Briefs in Primary Care Supplement